Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution?

AbCellera Biologics Inc. (NASDAQ:ABCL) is a must-buy penny stock to buy now. On November 13, at the Stifel 2025 Healthcare Conference, AbCellera Biologics Inc. (NASDAQ:ABCL) reaffirmed its strategic evolution into a company focused on developing clinical assets. The company will no longer operate under a partnership model but will develop its own assets backed by a strong financial position.

With over $500 million in cash and equivalents, AbCellera is focused on the development of ABCL635, a first-in-class antibody medicine for the non-hormonal treatment of moderate to severe menopausal hot flashes. The company is also working on ABCL575, an antibody for the treatment of moderate-to-severe atopic dermatitis (AD).

Even as the company continues to work on its clinical assets, strategic partnerships with big Pharma, including Eli Lilly and AbbVie, are crucial. The internal clinical assets are only seen as a presale activity for future licensing. Amid the new strategic focus, on November 7, TD Cowen analyst Brendan Smith reiterated a Buy rating, as Stifel Nicolaus analyst Stephen Wiley echoed similar sentiments with a Buy rating and a $7 price target.

AbCellera Biologics Inc. (NASDAQ:ABCL) is a clinical-stage biotechnology company that discovers and develops antibody-based medicines for a range of diseases, including cancer, metabolic and endocrine conditions, and autoimmune disorders.

While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.